EUVIMEDEUVIMED entdecken
Crossref

Novel cyclometalated iridium(III) complexes with a π-expansive benzothiophene ligand for enhanced photodynamic therapy against human osteosarcoma by disrupting Iron homeostasis

Zhewen Deng, Qing Zhang, Jie Zhu, Jiaqi Li, Mengyuan Zhang, Jitong Yuan, Zimei Wu, Qi Zhang, Rui Liu, Bo Ma

Bioorganic Chemistry · 2025

DOI: 10.1016/j.bioorg.2025.109121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Zhewen Deng und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, PR China. Hauptthemen laut MEDLINE: Iridium, Antineoplastic Agents, Photochemotherapy, Coordination Complexes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National College Students Innovation and Entrepreneurship Training Program, Jiangsu Province Natural Science Foundation, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma, a prevalent primary bone malignancy in adolescents, remains a therapeutic challenge owing to its high recurrence rate and resistance to conventional treatments. Integrating photodynamic therapy (PDT) with ferroptosis induction offers a promising anticancer strategy. However, the precise control of cancer-specific inducers remains elusive. In this study, we developed a novel Iridium (III) complex (Ir-X) incorporating a π-expansive 1-(benzo[b]thiophen-2-yl) isoquinoline ligand, which demonstrated exceptional photophysical properties, including a high singlet oxygen quantum yield, prolonged triplet excited state lifetime, and potent nanomolar cytotoxicity against osteosarcoma cells. These properties facilitate efficient generation of reactive oxygen species (ROS) under 525 nm laser irradiation. In vitro studies demonstrated that Ir-X-mediated PDT significantly reduced osteosarcoma cell viability by inducing ferroptosis, evidenced by increased intracellular iron accumulation, elevated lipid peroxidation, glutathione depletion, and mitochondrial dysfunction. Furthermore, the therapeutic potential of Ir-X was substantiated in xenograft models, where it significantly suppressed tumor growth without causing systemic toxicity in the major organs. Mechanistically, RNA sequencing and bioinformatic analyses revealed that Ir-X orchestrates a dual mechanism by upregulating NCOA4 expression and activating autophagy pathways, leading to enhanced ferritin degradation, iron release, and ultimately triggers ferroptosis. Genetic manipulation studies provided compelling evidence for the critical role of NCOA4, as its ablation substantially diminished the antitumor efficacy of Ir-X, whereas its overexpression amplified the therapeutic effects. These findings establish Ir-X as a promising therapeutic agent that synergistically induces ferroptosis through NCOA4-mediated ferritinophagy, establishing a fundamental basis for advancing iridium-based photosensitizers and pioneering therapeutic strategies against ferroptosis-vulnerable cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IridiumAntineoplastic AgentsPhotochemotherapyCoordination ComplexesOsteosarcomaIronPhotosensitizing AgentsThiophenesBone NeoplasmsHumansAnimalsLigandsMiceDrug Screening Assays, AntitumorMolecular StructureStructure-Activity RelationshipCell ProliferationDose-Response Relationship, DrugHomeostasisCell SurvivalCell Line, TumorReactive Oxygen SpeciesFerroptosis

Stichwörter der Autor:innen

FerritinophagyFerroptosisIridium (III) complexNCOA4Osteosarcoma

Substanzen

IridiumAntineoplastic AgentsCoordination ComplexesLigandsIronPhotosensitizing AgentsThiophenesReactive Oxygen Species

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, PR China.
  • School of Chemistry and Molecular Engineering, Nanjing Tech University, Nanjing 211816, PR China.
  • School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
  • School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, PR China. Electronic address: zhangqi@njtech.edu.cn.
  • School of Chemistry and Molecular Engineering, Nanjing Tech University, Nanjing 211816, PR China. Electronic address: rui.liu@njtech.edu.cn.
  • School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211816, PR China. Electronic address: mabo201012@njtech.edu.cn.

Förderung

  • National College Students Innovation and Entrepreneurship Training Program
  • Jiangsu Province Natural Science Foundation
  • Ministry of Education
  • Graduate Research and Innovation Projects of Jiangsu Province
  • National Key Research and Development Program of China

Zitieren

APA

Deng, Z., Zhang, Q., Zhu, J., Li, J., Zhang, M., Yuan, J., Wu, Z., Zhang, Q., Liu, R., & Ma, B. (2025). Novel cyclometalated iridium(III) complexes with a π-expansive benzothiophene ligand for enhanced photodynamic therapy against human osteosarcoma by disrupting Iron homeostasis. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.109121

Vancouver

Deng Z, Zhang Q, Zhu J, Li J, Zhang M, Yuan J, et al. Novel cyclometalated iridium(III) complexes with a π-expansive benzothiophene ligand for enhanced photodynamic therapy against human osteosarcoma by disrupting Iron homeostasis. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.109121

BibTeX
@article{Deng2025,
  author = {Deng, Zhewen and Zhang, Qing and Zhu, Jie and Li, Jiaqi and Zhang, Mengyuan and Yuan, Jitong and Wu, Zimei and Zhang, Qi and Liu, Rui and Ma, Bo},
  title = {Novel cyclometalated iridium(III) complexes with a π-expansive benzothiophene ligand for enhanced photodynamic therapy against human osteosarcoma by disrupting Iron homeostasis},
  journal = {Bioorganic Chemistry},
  year = {2025},
  doi = {10.1016/j.bioorg.2025.109121}
}
Kostenlos starten →